modafinil has been researched along with Depression in 23 studies
Modafinil: A benzhydryl acetamide compound, central nervous system stimulant, and CYP3A4 inducing agent that is used in the treatment of NARCOLEPSY and SLEEP WAKE DISORDERS.
modafinil : A racemate comprising equimolar amounts of armodafinil and (S)-modafinil. A central nervous system stimulant, it is used for the treatment of sleeping disorders such as narcolepsy, obstructive sleep apnoea, and shift-work sleep disorder. The optical enantiomers of modafinil have similar pharmacological actions in animals.
2-[(diphenylmethyl)sulfinyl]acetamide : A sulfoxide that is dimethylsulfoxide in which two hydrogens attached to one of the methyl groups are replaced by phenyl groups, while one hydrogen attached to the other methyl group is replaced by a carbamoyl (aminocarbonyl) group.
Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to examine the effect of modafinil on depression via a secondary data analysis of a randomized clinical trial of modafinil for fatigue in cancer patients." | 9.22 | Modafinil Moderates the Relationship Between Cancer-Related Fatigue and Depression in 541 Patients Receiving Chemotherapy. ( Conley, CC; Dakhil, S; Gross, H; Heckler, CE; Janelsins, MC; Kamen, CS; Morrow, GR; Mustian, KM; Palesh, OG; Peppone, LJ; Scalzo, AJ, 2016) |
| "Modafinil is a novel wake-promoting agent approved by the FDA ameliorating excessive daytime sleepiness (EDS) in three disorders: narcolepsy, shift work sleep disorder and obstructive sleep apnea." | 8.89 | Efficacy of modafinil on fatigue and excessive daytime sleepiness associated with neurological disorders: a systematic review and meta-analysis. ( Dong, Y; Han, X; Hou, L; Huang, C; Sheng, P; Wang, X; Yu, M, 2013) |
| "One retrospective study, 5 open-label trials, and 2 randomized controlled clinical trials met the inclusion criteria for assessment of residual symptoms of fatigue as assessed by commonly used fatigue subscales after modafinil administration." | 8.84 | Modafinil augmentation for residual symptoms of fatigue in patients with a partial response to antidepressants. ( Cates, ME; Freeman, MK; Lam, JY, 2007) |
| "Effects of modafinil were investigated (a) acutely in the forced swim test (FST) 1 h after administration of drug or placebo and (b) in a further experiment on cognition-related behaviour in rats after induction of depression-like changes using a restraint stress protocol for 15 days." | 7.75 | Depression-like deficits in rats improved by subchronic modafinil. ( Koch, H; Köhler, C; Krügel, U; Preiss, R; Regenthal, R, 2009) |
| "19] after taking 200 mg versus 100 mg and 0 mg of modafinil, while fluency increased linearly with dosage at a trend level [F(1,18) = 4." | 7.11 | A multi-pronged investigation of option generation using depression, PET and modafinil. ( Ang, YS; Belleau, EL; Boyden, S; Breiger, M; Brunner, D; Cusin, C; Dillon, DG; El Fakhri, G; Fava, M; Gelda, SE; Hayden, E; Hooker, J; Jahan, A; Kang, MS; Levine, MT; Meyer, AK; Normandin, M; Petibon, Y; Pizzagalli, DA; Schroder, H, 2022) |
| "IFN-alpha-induced depression is presumed to be composed of two overlapping syndromes: a depression-specific syndrome characterized by depressed mood, anxiety, and cognitive complaints, and a neurovegetative syndrome consisting of fatigue, anorexia, somatic pain complaints, and psychomotor retardation [1]." | 5.34 | Modafinil's use in combating interferon-induced fatigue. ( Balan, V; Krahn, LE; Martin, KA; Rosati, MJ, 2007) |
| "The aim of this study was to examine the effect of modafinil on depression via a secondary data analysis of a randomized clinical trial of modafinil for fatigue in cancer patients." | 5.22 | Modafinil Moderates the Relationship Between Cancer-Related Fatigue and Depression in 541 Patients Receiving Chemotherapy. ( Conley, CC; Dakhil, S; Gross, H; Heckler, CE; Janelsins, MC; Kamen, CS; Morrow, GR; Mustian, KM; Palesh, OG; Peppone, LJ; Scalzo, AJ, 2016) |
| "The use of traditional psychostimulants (methylphenidate and dexamphetamine) and stimulant-like drugs (modafinil and armodafinil) for the treatment of depression is a growing concern given the lack of research evidence supporting their effectiveness." | 4.93 | Stimulants for depression: On the up and up? ( Bassett, D; Boyce, P; Byrow, Y; Hopwood, M; Lyndon, W; Malhi, GS; Mulder, R; Murray, G; Porter, R; Singh, A, 2016) |
| "Modafinil is a novel wake-promoting agent approved by the FDA ameliorating excessive daytime sleepiness (EDS) in three disorders: narcolepsy, shift work sleep disorder and obstructive sleep apnea." | 4.89 | Efficacy of modafinil on fatigue and excessive daytime sleepiness associated with neurological disorders: a systematic review and meta-analysis. ( Dong, Y; Han, X; Hou, L; Huang, C; Sheng, P; Wang, X; Yu, M, 2013) |
| "Although most research to date has focused on the use of methylphenidate for the relief of symptoms such as asthenia and depression in cancer patients, there is growing interest in the use of modafinil, a psychostimulant with a structure and mechanism that differs from other drugs belonging to this group." | 4.87 | The use of psychostimulants in cancer patients. ( Centeno, C; Portela, MA; Rubiales, AS, 2011) |
| "One retrospective study, 5 open-label trials, and 2 randomized controlled clinical trials met the inclusion criteria for assessment of residual symptoms of fatigue as assessed by commonly used fatigue subscales after modafinil administration." | 4.84 | Modafinil augmentation for residual symptoms of fatigue in patients with a partial response to antidepressants. ( Cates, ME; Freeman, MK; Lam, JY, 2007) |
| "A total of 3354, 935 and 105 patients diagnosed with depression redeemed prescriptions for methylphenidate, modafinil or amphetamine/dexamphetamine/lisdexamphetamine, respectively." | 3.96 | The use of stimulants in depression: Results from a self-controlled register study. ( Brink, P; Nielsen, J; Rohde, C; Østergaard, SD, 2020) |
| "Effects of modafinil were investigated (a) acutely in the forced swim test (FST) 1 h after administration of drug or placebo and (b) in a further experiment on cognition-related behaviour in rats after induction of depression-like changes using a restraint stress protocol for 15 days." | 3.75 | Depression-like deficits in rats improved by subchronic modafinil. ( Koch, H; Köhler, C; Krügel, U; Preiss, R; Regenthal, R, 2009) |
| "19] after taking 200 mg versus 100 mg and 0 mg of modafinil, while fluency increased linearly with dosage at a trend level [F(1,18) = 4." | 3.11 | A multi-pronged investigation of option generation using depression, PET and modafinil. ( Ang, YS; Belleau, EL; Boyden, S; Breiger, M; Brunner, D; Cusin, C; Dillon, DG; El Fakhri, G; Fava, M; Gelda, SE; Hayden, E; Hooker, J; Jahan, A; Kang, MS; Levine, MT; Meyer, AK; Normandin, M; Petibon, Y; Pizzagalli, DA; Schroder, H, 2022) |
| "Modafinil was used in a randomized double-blind placebo-controlled design and was administered as follows: 400 mg/day for 26 days, then 300 mg/day for 30 days, and 200 mg/day for 31 days." | 2.82 | Dopamine Transporter Correlates and Occupancy by Modafinil in Cocaine-Dependent Patients: A Controlled Study With High-Resolution PET and [(11)C]-PE2I. ( Artiges, E; Bordas, N; Dubois, A; Dubol, M; Karila, L; Leroy, C; Mabondo, A; Marill, C; Martinot, JL; Reynaud, M; Trichard, C, 2016) |
| "Past modafinil use was reported by 2." | 2.74 | Modafinil and zolpidem use by emergency medicine residents. ( Ankel, FK; Asplin, BR; Flottemesch, TJ; Ling, LJ; Mason, EJ; McBeth, BD; McNamara, RM, 2009) |
| "Fatigue is the most common and debilitating symptom in multiple sclerosis (MS) and is believed to be distinctly different from fatigue seen in other chronic conditions." | 2.48 | Fatigue in multiple sclerosis - a brief review. ( Constantinescu, CS; Gran, B; Induruwa, I, 2012) |
| "Fatigue is among the most commonly reported symptoms of patients with cancer, with prevalence exceeding 60% in many studies." | 2.43 | Management of cancer-related fatigue. ( Hickok, JT; Morrow, GR; Mustian, K; Roscoe, JA; Shelke, AR, 2005) |
| "Fatigue is among the most common, yet least understood, symptoms of multiple sclerosis (MS) [1." | 2.41 | Fatigue in multiple sclerosis. ( Christodoulou, C; Krupp, LB, 2001) |
| "Modafinil is a wake-promoting agent that provides wide ranges of neurological effects." | 1.42 | Antidepressant-like effect of modafinil in mice: Evidence for the involvement of the dopaminergic neurotransmission. ( Farhoudi, M; Mahmoudi, J; Sabermarouf, B; Sadigh-Eteghad, S; Talebi, M, 2015) |
| "IFN-alpha-induced depression is presumed to be composed of two overlapping syndromes: a depression-specific syndrome characterized by depressed mood, anxiety, and cognitive complaints, and a neurovegetative syndrome consisting of fatigue, anorexia, somatic pain complaints, and psychomotor retardation [1]." | 1.34 | Modafinil's use in combating interferon-induced fatigue. ( Balan, V; Krahn, LE; Martin, KA; Rosati, MJ, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (34.78) | 29.6817 |
| 2010's | 12 (52.17) | 24.3611 |
| 2020's | 3 (13.04) | 2.80 |
| Authors | Studies |
|---|---|
| Ang, YS | 1 |
| Cusin, C | 1 |
| Petibon, Y | 1 |
| Dillon, DG | 1 |
| Breiger, M | 1 |
| Belleau, EL | 1 |
| Normandin, M | 1 |
| Schroder, H | 1 |
| Boyden, S | 1 |
| Hayden, E | 1 |
| Levine, MT | 1 |
| Jahan, A | 1 |
| Meyer, AK | 1 |
| Kang, MS | 1 |
| Brunner, D | 1 |
| Gelda, SE | 1 |
| Hooker, J | 1 |
| El Fakhri, G | 1 |
| Fava, M | 1 |
| Pizzagalli, DA | 1 |
| Rohde, C | 1 |
| Brink, P | 1 |
| Østergaard, SD | 1 |
| Nielsen, J | 1 |
| Omidi-Ardali, H | 1 |
| Badi, AG | 1 |
| Saghaei, E | 1 |
| Amini-Khoei, H | 1 |
| Zager, A | 1 |
| Brandão, WN | 1 |
| Margatho, RO | 1 |
| Peron, JP | 1 |
| Tufik, S | 1 |
| Andersen, ML | 1 |
| Kornum, BR | 1 |
| Palermo-Neto, J | 1 |
| Rubin, SM | 1 |
| Barsevick, AM | 1 |
| Irwin, MR | 1 |
| Hinds, P | 1 |
| Miller, A | 1 |
| Berger, A | 1 |
| Jacobsen, P | 1 |
| Ancoli-Israel, S | 1 |
| Reeve, BB | 1 |
| Mustian, K | 2 |
| O'Mara, A | 1 |
| Lai, JS | 1 |
| Fisch, M | 1 |
| Cella, D | 1 |
| Launois, SH | 1 |
| Tamisier, R | 1 |
| Lévy, P | 1 |
| Pépin, JL | 1 |
| Sheng, P | 1 |
| Hou, L | 1 |
| Wang, X | 2 |
| Huang, C | 1 |
| Yu, M | 1 |
| Han, X | 1 |
| Dong, Y | 1 |
| Mahmoudi, J | 1 |
| Farhoudi, M | 1 |
| Talebi, M | 1 |
| Sabermarouf, B | 1 |
| Sadigh-Eteghad, S | 1 |
| Conley, CC | 1 |
| Kamen, CS | 1 |
| Heckler, CE | 1 |
| Janelsins, MC | 1 |
| Morrow, GR | 2 |
| Peppone, LJ | 1 |
| Scalzo, AJ | 1 |
| Gross, H | 1 |
| Dakhil, S | 1 |
| Mustian, KM | 1 |
| Palesh, OG | 1 |
| Karila, L | 1 |
| Leroy, C | 1 |
| Dubol, M | 1 |
| Trichard, C | 1 |
| Mabondo, A | 1 |
| Marill, C | 1 |
| Dubois, A | 1 |
| Bordas, N | 1 |
| Martinot, JL | 1 |
| Reynaud, M | 1 |
| Artiges, E | 1 |
| Malhi, GS | 1 |
| Byrow, Y | 1 |
| Bassett, D | 1 |
| Boyce, P | 1 |
| Hopwood, M | 1 |
| Lyndon, W | 1 |
| Mulder, R | 1 |
| Porter, R | 1 |
| Singh, A | 1 |
| Murray, G | 1 |
| Dauvilliers, Y | 1 |
| Paquereau, J | 1 |
| Bastuji, H | 1 |
| Drouot, X | 1 |
| Weil, JS | 1 |
| Viot-Blanc, V | 1 |
| Regenthal, R | 1 |
| Koch, H | 1 |
| Köhler, C | 1 |
| Preiss, R | 1 |
| Krügel, U | 1 |
| McBeth, BD | 1 |
| McNamara, RM | 1 |
| Ankel, FK | 1 |
| Mason, EJ | 1 |
| Ling, LJ | 1 |
| Flottemesch, TJ | 1 |
| Asplin, BR | 1 |
| Rossetti, AO | 1 |
| Heinzer, RC | 1 |
| Tafti, M | 1 |
| Buclin, T | 1 |
| Portela, MA | 1 |
| Rubiales, AS | 1 |
| Centeno, C | 1 |
| Induruwa, I | 1 |
| Constantinescu, CS | 1 |
| Gran, B | 1 |
| Shelke, AR | 1 |
| Roscoe, JA | 1 |
| Hickok, JT | 1 |
| Martin, KA | 1 |
| Krahn, LE | 1 |
| Balan, V | 1 |
| Rosati, MJ | 1 |
| Lam, JY | 1 |
| Freeman, MK | 1 |
| Cates, ME | 1 |
| Krupp, LB | 1 |
| Christodoulou, C | 1 |
| Ferraro, L | 1 |
| Fuxe, K | 1 |
| Tanganelli, S | 1 |
| Tomasini, MC | 1 |
| Rambert, FA | 1 |
| Antonelli, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Feasibility Study of a Hypnosis Intervention and a Cognitive Behavioral Therapy Intervention to Reduce Fatigue in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer[NCT04999306] | 60 participants (Anticipated) | Interventional | 2023-05-17 | Recruiting | |||
| Effect of Resistance Training Variable Manipulation (Intensity and Volume) on Body Composition, Fatigability and Functional Capacity in Postmenopausal Breast Cancer Survivors.[NCT03644329] | 80 participants (Anticipated) | Interventional | 2018-05-13 | Recruiting | |||
| Observational Study of the Effect of Ozanimod on Fatigue in Multiple Sclerosis Patients[NCT05319093] | 40 participants (Anticipated) | Observational | 2022-04-30 | Not yet recruiting | |||
| Self-Management Program Based on Physical Exercises for People With Multiple Sclerosis With Mild Neurological Impairment: A Randomized Controlled Trial[NCT02607020] | 100 participants (Anticipated) | Interventional | 2015-12-31 | Recruiting | |||
| A PILOT STUDY OF INTRAVENOUS, SUBANESTHETIC DOSE OF KETAMINE VS PLACEBO, A CROSSOVER DESIGN, FOR MULTIPLE SCLEROSIS RELATED FATIGUE[NCT06064162] | Early Phase 1 | 20 participants (Anticipated) | Interventional | 2023-10-31 | Not yet recruiting | ||
| Randomized Controlled Trial of Exercise to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer[NCT02846389] | 24 participants (Actual) | Interventional | 2016-06-21 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for modafinil and Depression
| Article | Year |
|---|---|
Management of cognition and fatigue.
Topics: Animals; Antibodies, Monoclonal, Humanized; Benzhydryl Compounds; Cognition Disorders; Depression; D | 2013 |
On treatment but still sleepy: cause and management of residual sleepiness in obstructive sleep apnea.
Topics: Benzhydryl Compounds; Continuous Positive Airway Pressure; Depression; Disorders of Excessive Somnol | 2013 |
Efficacy of modafinil on fatigue and excessive daytime sleepiness associated with neurological disorders: a systematic review and meta-analysis.
Topics: Benzhydryl Compounds; Depression; Disorders of Excessive Somnolence; Fatigue; Humans; Modafinil | 2013 |
Stimulants for depression: On the up and up?
Topics: Amphetamine; Antidepressive Agents; Benzhydryl Compounds; Bipolar Disorder; Central Nervous System S | 2016 |
The use of psychostimulants in cancer patients.
Topics: Adult; Antineoplastic Agents; Asthenia; Benzhydryl Compounds; Central Nervous System Stimulants; Chi | 2011 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Management of cancer-related fatigue.
Topics: Antidepressive Agents; Benzhydryl Compounds; Depression; Fatigue; Glucocorticoids; Humans; Modafinil | 2005 |
Modafinil augmentation for residual symptoms of fatigue in patients with a partial response to antidepressants.
Topics: Antidepressive Agents; Benzhydryl Compounds; Central Nervous System Stimulants; Depression; Fatigue; | 2007 |
Fatigue in multiple sclerosis.
Topics: Amantadine; Autoimmune Diseases; Benzhydryl Compounds; Brain; Case Management; Central Nervous Syste | 2001 |
4 trials available for modafinil and Depression
| Article | Year |
|---|---|
A multi-pronged investigation of option generation using depression, PET and modafinil.
Topics: Adult; Cross-Over Studies; Depression; Depressive Disorder, Major; Dopamine; Humans; Modafinil; Posi | 2022 |
Modafinil Moderates the Relationship Between Cancer-Related Fatigue and Depression in 541 Patients Receiving Chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Depression; Double-Blind Method; F | 2016 |
Dopamine Transporter Correlates and Occupancy by Modafinil in Cocaine-Dependent Patients: A Controlled Study With High-Resolution PET and [(11)C]-PE2I.
Topics: Adult; Benzhydryl Compounds; Brain; Cocaine-Related Disorders; Craving; Decision Making; Depression; | 2016 |
Modafinil and zolpidem use by emergency medicine residents.
Topics: Adult; Akathisia, Drug-Induced; Amnesia; Anorexia; Benzhydryl Compounds; Central Nervous System Stim | 2009 |
10 other studies available for modafinil and Depression
| Article | Year |
|---|---|
The use of stimulants in depression: Results from a self-controlled register study.
Topics: Adult; Amphetamine; Central Nervous System Stimulants; Denmark; Depression; Dextroamphetamine; Drug | 2020 |
Nitric oxide mediates the antidepressant-like effect of modafinil in mouse forced swimming and tail suspension tests.
Topics: Animals; Antidepressive Agents; Arginine; Depression; Hindlimb Suspension; Hippocampus; Mice; Modafi | 2020 |
The wake-promoting drug Modafinil prevents motor impairment in sickness behavior induced by LPS in mice: Role for dopaminergic D1 receptor.
Topics: Animals; Anxiety; Benzazepines; Benzhydryl Compounds; Brain; Cell Movement; Depression; Disease Mode | 2018 |
Recommendations for high-priority research on cancer-related fatigue in children and adults.
Topics: Adult; Anxiety; Benzhydryl Compounds; Bupropion; Central Nervous System Stimulants; Child; Clinical | 2013 |
Recommendations for high-priority research on cancer-related fatigue in children and adults.
Topics: Adult; Anxiety; Benzhydryl Compounds; Bupropion; Central Nervous System Stimulants; Child; Clinical | 2013 |
Recommendations for high-priority research on cancer-related fatigue in children and adults.
Topics: Adult; Anxiety; Benzhydryl Compounds; Bupropion; Central Nervous System Stimulants; Child; Clinical | 2013 |
Recommendations for high-priority research on cancer-related fatigue in children and adults.
Topics: Adult; Anxiety; Benzhydryl Compounds; Bupropion; Central Nervous System Stimulants; Child; Clinical | 2013 |
Antidepressant-like effect of modafinil in mice: Evidence for the involvement of the dopaminergic neurotransmission.
Topics: Animals; Antidepressive Agents; Benzhydryl Compounds; Depression; Dopamine Antagonists; Dose-Respons | 2015 |
Psychological health in central hypersomnias: the French Harmony study.
Topics: Adult; Antidepressive Agents; Benzhydryl Compounds; Cataplexy; Central Nervous System Stimulants; Co | 2009 |
Depression-like deficits in rats improved by subchronic modafinil.
Topics: Animals; Antidepressive Agents; Attention; Behavior, Animal; Benzhydryl Compounds; Central Nervous S | 2009 |
Rapid occurrence of depression following addition of sodium oxybate to modafinil.
Topics: Adjuvants, Anesthesia; Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Depression; D | 2010 |
Modafinil's use in combating interferon-induced fatigue.
Topics: Aged; Antiviral Agents; Benzhydryl Compounds; Central Nervous System Stimulants; Depression; Fatigue | 2007 |
Differential enhancement of dialysate serotonin levels in distinct brain regions of the awake rat by modafinil: possible relevance for wakefulness and depression.
Topics: Amygdala; Animals; Benzhydryl Compounds; Brain; Central Nervous System Stimulants; Depression; Front | 2002 |